Muhammad R Afzal1, Anweshan Samanta1, Zubair I Shah1, Vinodh Jeevanantham1, Ahmed Abdel-Latif1, Ewa K Zuba-Surma1, Buddhadeb Dawn2. 1. From the Division of Cardiovascular Diseases, Cardiovascular Research Institute, and the Midwest Stem Cell Therapy Center, University of Kansas Medical Center, Kansas City (M.R.A., A.S., Z.I.S., B.D.); Heart and Vascular Specialists of Oklahoma, Oklahoma City (V.J.); Division of Cardiology, University of Kentucky, Lexington (A.A.-L.); and Department of Cell Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland (E.K.Z.-S). 2. From the Division of Cardiovascular Diseases, Cardiovascular Research Institute, and the Midwest Stem Cell Therapy Center, University of Kansas Medical Center, Kansas City (M.R.A., A.S., Z.I.S., B.D.); Heart and Vascular Specialists of Oklahoma, Oklahoma City (V.J.); Division of Cardiology, University of Kentucky, Lexington (A.A.-L.); and Department of Cell Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland (E.K.Z.-S). bdawn@kumc.edu.
Abstract
RATIONALE: Notwithstanding the uncertainties about the outcomes of bone marrow cell (BMC) therapy for heart repair, further insights are critically needed to improve this promising approach. OBJECTIVE: To delineate the true effect of BMC therapy for cardiac repair and gain insights for future trials through systematic review and meta-analysis of data from eligible randomized controlled trials. METHODS AND RESULTS: Database searches through August 2014 identified 48 eligible randomized controlled trials (enrolling 2602 patients). Weighted mean differences for changes in left ventricular (LV) ejection fraction, infarct size, LV end-systolic volume, and LV end-diastolic volume were analyzed with random-effects meta-analysis. Compared with standard therapy, BMC transplantation improved LV ejection fraction (2.92%; 95% confidence interval, 1.91-3.92; P<0.00001), reduced infarct size (-2.25%; 95% confidence interval, -3.55 to -0.95; P=0.0007) and LV end-systolic volume (-6.37 mL; 95% confidence interval, -8.95 to -3.80; P<0.00001), and tended to reduce LV end-diastolic volume (-2.26 mL; 95% confidence interval, -4.59 to 0.07; P=0.06). Similar effects were noted when data were analyzed after excluding studies with discrepancies in reporting of outcomes. The benefits also persisted when cardiac catheterization was performed in control patients as well. Although imaging modalities partly influenced the outcomes, LV ejection fraction improved in BMC-treated patients when assessed by magnetic resonance imaging. Early (<48 hours) BMC injection after myocardial Infarction was more effective in reducing infarct size, whereas BMC injection between 3 and 10 days proved superior toward improving systolic function. A minimum of 50 million BMCs seemed to be necessary, with limited additional benefits seen with increasing cell numbers. BMC therapy was safe and improved clinical outcomes, including all-cause mortality, recurrent myocardial Infarction, ventricular arrhythmia, and cerebrovascular accident during follow-up, albeit with differences between acute myocardial Infarction and chronic ischemic heart disease subgroups. CONCLUSIONS: Transplantation of adult BMCs improves LV ejection fraction, reduces infarct size, and ameliorates remodeling in patients with ischemic heart disease. These effects are upheld in the analyses of studies using magnetic resonance imaging and also after excluding studies with discrepant reporting of outcomes. BMC transplantation may also reduce the incidence of death, recurrent myocardial Infarction, ventricular arrhythmia, and cerebrovascular accident during follow-up.
RATIONALE: Notwithstanding the uncertainties about the outcomes of bone marrow cell (BMC) therapy for heart repair, further insights are critically needed to improve this promising approach. OBJECTIVE: To delineate the true effect of BMC therapy for cardiac repair and gain insights for future trials through systematic review and meta-analysis of data from eligible randomized controlled trials. METHODS AND RESULTS: Database searches through August 2014 identified 48 eligible randomized controlled trials (enrolling 2602 patients). Weighted mean differences for changes in left ventricular (LV) ejection fraction, infarct size, LV end-systolic volume, and LV end-diastolic volume were analyzed with random-effects meta-analysis. Compared with standard therapy, BMC transplantation improved LV ejection fraction (2.92%; 95% confidence interval, 1.91-3.92; P<0.00001), reduced infarct size (-2.25%; 95% confidence interval, -3.55 to -0.95; P=0.0007) and LV end-systolic volume (-6.37 mL; 95% confidence interval, -8.95 to -3.80; P<0.00001), and tended to reduce LV end-diastolic volume (-2.26 mL; 95% confidence interval, -4.59 to 0.07; P=0.06). Similar effects were noted when data were analyzed after excluding studies with discrepancies in reporting of outcomes. The benefits also persisted when cardiac catheterization was performed in control patients as well. Although imaging modalities partly influenced the outcomes, LV ejection fraction improved in BMC-treated patients when assessed by magnetic resonance imaging. Early (<48 hours) BMC injection after myocardial Infarction was more effective in reducing infarct size, whereas BMC injection between 3 and 10 days proved superior toward improving systolic function. A minimum of 50 million BMCs seemed to be necessary, with limited additional benefits seen with increasing cell numbers. BMC therapy was safe and improved clinical outcomes, including all-cause mortality, recurrent myocardial Infarction, ventricular arrhythmia, and cerebrovascular accident during follow-up, albeit with differences between acute myocardial Infarction and chronic ischemic heart disease subgroups. CONCLUSIONS: Transplantation of adult BMCs improves LV ejection fraction, reduces infarct size, and ameliorates remodeling in patients with ischemic heart disease. These effects are upheld in the analyses of studies using magnetic resonance imaging and also after excluding studies with discrepant reporting of outcomes. BMC transplantation may also reduce the incidence of death, recurrent myocardial Infarction, ventricular arrhythmia, and cerebrovascular accident during follow-up.
Authors: Alexander Hirsch; Robin Nijveldt; Pieter A van der Vleuten; Jan G P Tijssen; Willem J van der Giessen; René A Tio; Johannes Waltenberger; Jurrien M ten Berg; Pieter A Doevendans; Wim R M Aengevaeren; Jaap Jan Zwaginga; Bart J Biemond; Albert C van Rossum; Jan J Piek; Felix Zijlstra Journal: Eur Heart J Date: 2010-12-10 Impact factor: 29.983
Authors: C M O'Connor; W R Hathaway; E R Bates; J D Leimberger; K N Sigmon; D J Kereiakes; B S George; J K Samaha; C W Abbottsmith; R J Candela; E J Topol; R M Califf Journal: Am Heart J Date: 1997-06 Impact factor: 4.749
Authors: Gerd P Meyer; Kai C Wollert; Joachim Lotz; Jan Steffens; Peter Lippolt; Stephanie Fichtner; Hartmut Hecker; Arnd Schaefer; Lubomir Arseniev; Bernd Hertenstein; Arnold Ganser; Helmut Drexler Journal: Circulation Date: 2006-03-06 Impact factor: 29.690
Authors: Lian R Gao; Xue T Pei; Qing A Ding; Yu Chen; Ning K Zhang; Hai Y Chen; Zhi G Wang; Yun F Wang; Zhi M Zhu; Tian C Li; Hui L Liu; Zi C Tong; Yong Yang; Xue Nan; Feng Guo; Jian L Shen; Yan H Shen; Jian J Zhang; Yu X Fei; Hong T Xu; Li H Wang; Hai T Tian; Da Q Liu; Ye Yang Journal: Int J Cardiol Date: 2013-05-04 Impact factor: 4.164
Authors: Volker Schächinger; Sandra Erbs; Albrecht Elsässer; Werner Haberbosch; Rainer Hambrecht; Hans Hölschermann; Jiangtao Yu; Roberto Corti; Detlef G Mathey; Christian W Hamm; Tim Süselbeck; Birgit Assmus; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher Journal: N Engl J Med Date: 2006-09-21 Impact factor: 91.245
Authors: Hung-Fat Tse; Sukumaran Thambar; Yok-Lam Kwong; Philip Rowlings; Greg Bellamy; Jane McCrohon; Paul Thomas; Bruce Bastian; John K F Chan; Gladys Lo; Chi-Lai Ho; Wing-Sze Chan; Raymond Y Kwong; Anthony Parker; Thomas H Hauser; Jenny Chan; Daniel Y T Fong; Chu-Pak Lau Journal: Eur Heart J Date: 2007-11-05 Impact factor: 29.983
Authors: José Suárez de Lezo; Concepción Herrera; Manuel Pan; Miguel Romero; Djordje Pavlovic; José Segura; Joaquín Sánchez; Soledad Ojeda; Antonio Torres Journal: Rev Esp Cardiol Date: 2007-04 Impact factor: 4.753
Authors: R Goekmen Turan; I Bozdag-T; J Ortak; S Kische; I Akin; H Schneider; C H Turan; T C Rehders; M Rauchhaus; T Kleinfeldt; C Belu; M Brehm; S Yokus; S Steiner; K Sahin; C A Nienaber; H Ince Journal: Stem Cell Rev Rep Date: 2011-09 Impact factor: 5.739